Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease using Multiparametric Magnetic Resonance Imaging (TREASURE-CKD)
Latest Information Update: 28 Apr 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Obesity
- Focus Pharmacodynamics
- Acronyms TREASURE-CKD
- Sponsors Eli Lilly and Company
Most Recent Events
- 20 Apr 2025 Planned End Date changed from 1 Feb 2026 to 1 Oct 2026.
- 20 Apr 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Sep 2026.
- 03 Dec 2024 Planned End Date changed from 26 Feb 2026 to 1 Feb 2026.